Who can benefit more from its twelve-week treatment: A prospective cohort study of blonanserin for patients with schizophrenia

Table 5 Multivariate analysis of the influencing factors of brief psychiatric rating scale: Score reduction in non-acute phase patients with prominent negative symptoms at baseline

Characteristic	β	95%CI	P value
Baseline blunted affect score	N/A	N/A	0.061
≤ 3	0.00	N/A	N/A
≥ 4	2.45	-0.12 to 5.01	N/A
Disease duration (months)	-0.02	-0.04 to 0.01	0.217
Previous onset	-0.38	-0.63 to -0.13	0.003
Mean daily dose of concomitant anti-psychiatrics1	-0.01	-0.01 to 0.00	0.011
Baseline BPRS score	0.34	0.27 to 0.41	< 0.001
Number of types of sedative-hypnotic agents	-2.53	-4.17 to -0.90	0.003

¹Chlorpromazine equivalent dose.

CI: Confidence interval; BPRS: Brief psychiatric rating scale; N/A: Not applicable.